EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Myc upregulates Ggct, γ‐glutamylcyclotransferase to promote development of p53 ‐deficient osteosarcoma

Tomoya Ueno, Shohei Otani, Yuki Date iD, Yu Katsuma, Yuma Nagayoshi, Tomoko Ito, Hiromi Ii, Susumu Kageyama, Susumu Nakata iD, Kosei Ito iD

Cancer Science · 2024

DOI: 10.1111/cas.16255 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Science, 2024. Verfasst von Tomoya Ueno und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Tumor Biology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan. Hauptthemen laut MEDLINE: Osteosarcoma, gamma-Glutamylcyclotransferase, Tumor Suppressor Protein p53, Up-Regulation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Funding Program for Next Generation World-Leading Researchers, Japan, Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Osteosarcoma (OS) in humans is characterized by alterations in the TP53 gene. In mice, loss of p53 triggers OS development, for which c‐Myc (Myc) oncogenicity is indispensable. However, little is known about which genes are targeted by Myc to promote tumorigenesis. Here, we examined the role of γ‐glutamylcyclotransferase (Ggct) which is a component enzyme of the γ‐glutamyl cycle essential for glutathione homeostasis, in human and mouse OS development. We found that GGCT is a poor prognostic factor for human OS, and that deletion of Ggct suppresses p53 ‐deficient osteosarcomagenesis in mice. Myc upregulates Ggct directly by binding to the Ggct promoter, and deletion of a Myc binding site therein by genome editing attenuated the tumorigenic potential of p53 ‐deficient OS cells. Taken together, these results show a rationale that GGCT is widely upregulated in cancer cells and solidify its suitability as a target for anticancer drugs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Osteosarcomagamma-GlutamylcyclotransferaseTumor Suppressor Protein p53Up-RegulationProto-Oncogene Proteins c-mycBone NeoplasmsAnimalsHumansMiceGene Expression Regulation, NeoplasticCell Line, TumorPromoter Regions, GeneticFemaleMalePrognosisCarcinogenesis

Stichwörter der Autor:innen

GgctMycglutathioneosteosarcomap53

Substanzen

gamma-GlutamylcyclotransferaseTumor Suppressor Protein p53Proto-Oncogene Proteins c-mycGGCT protein, humanTP53 protein, humanMYC protein, human

Autor:innen und Institutionen

  • Department of Molecular Tumor Biology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan.
  • Department of Clinical Oncology, Kyoto Pharmaceutical University, Kyoto, Japan.
  • Department of Urology, Shiga University of Medical Science, Otsu, Japan.

ORCID-Profile: Yuki Date, Susumu Nakata, Kosei Ito

Förderung

  • Funding Program for Next Generation World-Leading Researchers, Japan
  • Japan Society for the Promotion of Science

Zitieren

APA

Ueno, T., Otani, S., Date, Y., Katsuma, Y., Nagayoshi, Y., Ito, T., Ii, H., Kageyama, S., Nakata, S., & Ito, K. (2024). Myc upregulates Ggct, γ‐glutamylcyclotransferase to promote development of p53 ‐deficient osteosarcoma. Cancer Science. https://doi.org/10.1111/cas.16255

Vancouver

Ueno T, Otani S, Date Y, Katsuma Y, Nagayoshi Y, Ito T, et al. Myc upregulates Ggct, γ‐glutamylcyclotransferase to promote development of p53 ‐deficient osteosarcoma. Cancer Science. 2024. doi:10.1111/cas.16255

BibTeX
@article{Ueno2024,
  author = {Ueno, Tomoya and Otani, Shohei and Date, Yuki and Katsuma, Yu and Nagayoshi, Yuma and Ito, Tomoko and Ii, Hiromi and Kageyama, Susumu and Nakata, Susumu and Ito, Kosei},
  title = {Myc upregulates Ggct, γ‐glutamylcyclotransferase to promote development of p53 ‐deficient osteosarcoma},
  journal = {Cancer Science},
  year = {2024},
  doi = {10.1111/cas.16255}
}
Kostenlos starten →